Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/vaccines9030214 http://scihub22266oqcxt.onion/10.3390/vaccines9030214 33802467!7999656!33802467     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Vaccines+(Basel) 2021 ; 9 (3): ä Nephropedia Template TP {{tp|p=33802467|t=2021. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies |pdf=|usr=}}{{33802467}} gab.com Text Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies JO: Vaccines (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=33802467 #FOAvip Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in clinical development and 173 are in the pre-clinical phase. Five types of vaccines are currently approved for emergency use in many countries (Inactivated, Sinopharm; Viral-vector, Astrazeneca, and Gamaleya Research Institute; mRNA, Moderna, and BioNTech/Pfizer). The main challenge in this pandemic was the availability to produce an effective vaccine to be distributed to the world's population in a short time. Herein, we developed a whole virus NRC-VACC-01 inactivated candidate SARS-CoV-2 vaccine and tested its safety and immunogenicity in laboratory animals. In the preclinical studies, we used four experimental animals (mice, rats, guinea pigs, and hamsters). Antibodies were detected as of week three post vaccination and continued up to week ten in the four experimental models. Safety evaluation of NRC-VACC-01 inactivated candidate vaccine in rats revealed that the vaccine was highly tolerable. By studying the effect of booster dose in the immunological profile of vaccinated mice, we observed an increase in neutralizing antibody titers after the booster shot, thus a booster dose was highly recommended after week three or four. Challenge infection of hamsters showed that the vaccinated group had lower morbidity and shedding than the control group. A phase I clinical trial will be performed to assess safety in human subjects. Twit Text FOAVip Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies ????Vaccines (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=33802467 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33802467 #FOAvip English Wikipedia <ref>{{Cite pmid|33802467}}</ref> Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies #MMPMID33802467 Kandeil A; Mostafa A; Hegazy RR; El-Shesheny R; El Taweel A; Gomaa MR; Shehata M; Elbaset MA; Kayed AE; Mahmoud SH; Moatasim Y; Kutkat O; Yassen NN; Shabana ME; GabAllah M; Kamel MN; Abo Shama NM; El Sayes M; Ahmed AN; Elalfy ZS; Mohamed BM; Abd El-Fattah SN; El Hariri HM; Abdel Kader M; Azmy O; Kayali G; Ali MA Vaccines (Basel) 2021[Mar]; 9 (3): ä PMID33802467show ga Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in clinical development and 173 are in the pre-clinical phase. Five types of vaccines are currently approved for emergency use in many countries (Inactivated, Sinopharm; Viral-vector, Astrazeneca, and Gamaleya Research Institute; mRNA, Moderna, and BioNTech/Pfizer). The main challenge in this pandemic was the availability to produce an effective vaccine to be distributed to the world's population in a short time. Herein, we developed a whole virus NRC-VACC-01 inactivated candidate SARS-CoV-2 vaccine and tested its safety and immunogenicity in laboratory animals. In the preclinical studies, we used four experimental animals (mice, rats, guinea pigs, and hamsters). Antibodies were detected as of week three post vaccination and continued up to week ten in the four experimental models. Safety evaluation of NRC-VACC-01 inactivated candidate vaccine in rats revealed that the vaccine was highly tolerable. By studying the effect of booster dose in the immunological profile of vaccinated mice, we observed an increase in neutralizing antibody titers after the booster shot, thus a booster dose was highly recommended after week three or four. Challenge infection of hamsters showed that the vaccinated group had lower morbidity and shedding than the control group. A phase I clinical trial will be performed to assess safety in human subjects. äImmunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Precli(epmc).pdf DeepDyve Pubget Overpricing